Even firms with candidates by now inside the later levels of screening remain going to involve many yrs to gather and method the info and, must points pan out, time to work with regulators to protected approval. Launching the drug is another issue fully and shoring up adequate supplies has tested hard even for firms the size of Lilly and Novo, who'